Health Catalyst (HCAT) Fundamental Analysis: Revenue, Earnings & Valuation

8.93 / 10

Outperform

Fundamentally, HCAT scores 8.9/10, driven by solid equity ratio (1.045) and strong shareholders’ equity‑to‑liabilities (0.957). Asset‑MV and net‑income‑revenue are favorable. However, ROE, cash‑flow growth and operating cash‑flow ratios are negative, tempering the outlook.

Analysis Checks(7/10)

Shareholders’ equity attributable to parent company / Total liabilities (%)

Value0.96

Score3/3

Weight16.26%

1M Return3.11%

ROE (diluted) (YoY growth rate %)

Value-69.81

Score0/3

Weight-10.93%

1M Return-2.74%

Equity ratio (Total liabilities / Shareholders’ equity attributable to parent company) (%)

Value1.05

Score3/3

Weight15.65%

1M Return2.99%

Net cash flow from operating activities / Operating revenue (%)

Value0.23

Score1/3

Weight-5.58%

1M Return-1.19%

Net income-Revenue

Value-0.04

Score2/3

Weight4.64%

1M Return0.98%

Basic earnings per share (YoY growth rate %)

Value-121.74

Score2/3

Weight5.57%

1M Return1.05%

Net cash flow from operating activities (YoY growth rate %)

Value-94.98

Score0/3

Weight-14.53%

1M Return-3.51%

Diluted earnings per share (YoY growth rate %)

Value-121.74

Score2/3

Weight8.37%

1M Return1.56%

Net profit attributable to parent company shareholders (YoY growth rate %)

Value-156.07

Score2/3

Weight2.51%

1M Return0.49%

Asset-MV

Value-0.55

Score3/3

Weight78.04%

1M Return12.37%

Is HCAT fundamentally strong?

HCAT scores 8.93/10 on fundamentals and holds a Discounted valuation at present. Backed by its -58.26% ROE, -57.20% net margin, -0.46 P/E ratio, 0.33 P/B ratio, and -121.74% earnings growth, these metrics solidify its Outperform investment rating.